Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Univariate analysis of PFS and OS in our study population

From: Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

  p value
mPFS mOS
Tumor response rate to axitinib
 DCR < 0.0000001 < 0.0000001
 ORR < 0.0000001 0.000026
Tumor response rate to prior sunitinib
 DRC 0.00031 0.094
 ORR 0.0011 0.049
Duration prior sunitinib treatment ≥ 13.1 vs < 13.1 mo 0.21 0.151
HENG score 0.066 0.002
ECOG PS 0.026 0.003
Prior nephrectomy 0.001 0.000004
G3 blood pressure 0.017 0.017